12:29 PM EDT, 05/01/2025 (MT Newswires) -- Design Therapeutics ( DSGN ) said Thursday its experimental DT-168 eye drops to potentially treat Fuchs endothelial corneal dystrophy were well-tolerated in a phase 1 trial.

The company said no serious side effects nor eye-related issues were reported. No treatment was discontinued due to adverse side effects, Design added.

The company said it expects to begin a phase 2 biomarker trial in patients with Fuchs endothelial corneal dystrophy in H2, with results anticipated in 2026.

The study will enroll FECD patients scheduled for corneal transplant surgery, the company added.

Shares of the company were down 3.3% in recent trading.

Price: 4.70, Change: -0.16, Percent Change: -3.29